Treatment of a patient with severe haemophilia A presenting with left extra pleural haematoma and diagnosed with inhibitors – case report

Arijit Das; Anupam Dutta; Ramanan BBV; Sanchu TK Sreeraj

doi:10.2478/jhp-2022-0010

Abstract

Abstract

Haemophilia is an inherited X-linked bleeding disorder characterised by a deficiency or absence of clotting factor VIII (haemophilia A) or IX (haemophilia B), which can cause musculoskeletal bleeding. The standard treatment for haemophilia is with factor concentrates to replace the missing or deficient clotting factor. However, there is a risk that the immune system develops antibodies against the exogenous factor, known as inhibitors. Managing patients with haemophilia and inhibitors who develop bleeding in unusual sites can be challenging for the treating physician. Here, we present a rare case of patient with severe haemophilia A who was diagnosed with inhibitors after developing bleeding in the left posterior chest wall (extra pleural haematoma). The patient was successfully managed with activated prothrombin complex concentrate (aPCC) (FEIBA: FVIII inhibitor bypassing activity; Baxter AG), and the pain and swelling gradually resolved over three weeks. This case emphasises the importance of clinical suspicion of inhibitor formation in a patient already diagnosed with haemophilia A presenting with unusual bleeding that does not respond to standard treatment.

Article

View Full Article

References

1. Soucie JM, Evatt B, Jackson D; Hemophilia Surveillance Systems Project Investigators. Occurrence of hemophilia in the United States. Am J Hematol 1998;59(4):288–94. doi: https://doi.org/10.1002/(sici)1096-8652(199812)59:4<288::aidajh4>3.0.co;2-i.
2. Iorio A, Stonebraker JS, Chambost H, et al. Establishing the prevalence and prevalence at birth of hemophilia in males. A meta-analytic approach using national registries. Ann Intern Med 2019; 171(8): 540–546. doi: https://doi.org/10.7326/M19-1208.
3. Morais SA, du Preez HE, Akhtar MR, Cross S, Isenberg DA. Musculoskeletal complications of haematological disease. Rheumatology (Oxford) 2016; 55(6): 968–81. doi: https://doi.org/10.1093/rheumatology/kev360.
4. Dutta A, Dutta TS, Dey P. Clinical profile of haemophilia patients of upper Assam—a hospital-based study. J Evol Med Dent Sci 2017;6(37): 2990–4.
5. Gavrel M, Rafowicz A, D’Oiron R, Franchi-Abella S, Lambert T, Adamsbaum C. Imaging features of atypical bleeds in young patients with hemophilia. Diagn Interv Imaging 2019; 100(3): 135–45. doi: https://doi.org/10.1016/j.diii.2018.11.010.
6. Eshghi P, Khafafpour Z, Malek F, Habibpanah B. Massive spontaneous hemothorax in a child with hemophilia. Iran J Blood Cancer 2019; 11(4): 148–9.
7. Carcao M, Goudemand J. Inhibitors in Hemophilia: A Primer. Fifth edition. 2018. Montréal: World Federation of Hemophilia. Available at https://www1.wfh.org/publication/files/pdf-1122.pdf (accessed 13 April 2022).
8. Oldenburg J, Mahlangu J, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 2017; 377(9): 809–818. doi: https://doi.org/10.1056/NEJMoa1703068.
9. Young G, Callaghan M, Dunn A, Kruse-Jarres R, Pipe S. Emicizumab for hemophilia A with factor VIII inhibitors. Expert Rev Hematol 2018; 11(11): 835–846. doi: https://doi.org/10.1080/17474086.2018.1531701.
10. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9(4): 418–35. doi: https://doi.org/10.1046/j.1365-2516.2003.00780.x.
11. Pinto P, Shelar T, Nawadkar V, et al. The epidemiology of FVIII inhibitors in Indian haemophilia A patients. Indian J Hematol Blood Transfus 2014; 30(4):356–63. doi: https://doi.org/10.1007/s12288-014-0342-z.
12. Oldenburg J, Schröder J, Brackmann HH, Müller-Reible C, Schwaab R, Tuddenham E. Environmental and genetic factors influencing inhibitor development. Semin Hematol 2004; 41(1 Suppl 1); 82–8. doi: https://doi.org/10.1053/j.seminhematol.2003.11.016.
13. Lorenzo JI, López A, Altisent C, Aznar JA. Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age. Br J Haematol 2001; 113(3): 600–3. doi: https://doi.org/10.1046/j.1365-2141.2001.02828.x.
14. Witmer C, Young G. Factor VIII inhibitors in hemophilia A: rationale and latest evidence. Ther Adv Hematol 2013; 4(1): 59–72. doi: https://doi.org/10.1177/2040620712464509.
15. Sachdeva A, Gunasekaran V, Ramya HN, et al. Consensus statement of the Indian Academy of Pediatrics in diagnosis and management of hemophilia. Indian Pediatr 2018; 55(7): 582–90.
16. Radhakrishnan N, Shankar R, Maji M, Rana M. Initial experience of Emicizumab prophylaxis in children with inhibitor positive severe hemophilia A from a single center in India. Pediatr Hematol Oncol J 2021; 6(2): 97–99. doi: https://doi.org/10.1016/j.phoj.2021.03.0004.
17. Ljung R, Auerswald G, Benson G, et al. Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficult-to-treat patients. Eur J Haematol 2019; 102(2): 111–22. doi: https://doi.org/10.1111/ejh.13193.

PDF Download

Download PDF

Open in full-page viewer

Authors

Arijit Das

darijit1992@gmail.com

Assam Medical College and Hospital, Dibrugarh, Assam, India
Anupam Dutta

Assam Medical College and Hospital, Dibrugarh, Assam, India
Ramanan BBV

Assam Medical College and Hospital, Dibrugarh, Assam, India
Sanchu TK Sreeraj

Assam Medical College and Hospital, Dibrugarh, Assam, India